作者: Vital P Costa , Alon Harris , Einar Stefánsson , Josef Flammer , Gunter K Krieglstein
DOI: 10.1016/S1350-9462(03)00064-8
关键词:
摘要: Based on the body of evidence implicating ocular blood flow disturbances in pathogenesis glaucoma, there is great interest investigation effects antiglaucoma drugs and systemic medications various vascular beds. The primary aim this article was to review current data available flow. We performed a literature search November 2002, which consisted textword MEDLINE for years 1968-2002. results suggest that severe lack well-designed long-term studies investigating glaucomatous patients. However, among 136 articles dealing with effect flow, only 36 (26.5%) investigated glaucoma Among these articles, 3 (8.3%) were studies, 16 (44.4%) double-masked, randomized, prospective trials. 33 describing 11 (33.3%) patients, one (9.1%) trial. preliminary data, we would intimate few have potential directly improve Unoprostone appears reproducible antiendothelin-1 effect, betaxolol may exert calcium-channel blocker action, apraclonidine consistently leads anterior segment vasoconstriction, carbonic anhydrase inhibitors seem accelerate retinal circulation. Longitudinal, prospective, randomized trials are needed investigate vasoactive substances no hypotensive progression glaucoma.